LIBRETTO-001 Regimen Overview
A discussion on the LIBRETTO-001 trial design and results, and consideration of how RET inhibitors differ from approved multikinase inhibitors in treating NSCLC and thyroid cancer.
Related Articles
NuTide:323 Study of NUC-3373 Regimen in Second-Line CRC is Discontinued
The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued.
ESMO Congress
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
sNDA Withdrawn for Fruquitinib Plus Paclitaxel in Second-Line Gastric Cancer in China
The supplemental new drug application for fruquintinib plus paclitaxel in second-line gastric cancer in China has been voluntarily withdrawn.
TP53 Mutations Have Strong Prognostic Value for PFS and OS Outcomes in CLL
Consuelo Bertossi, MD, discusses research elucidating the role and prognostic significance of TP53 mutations in chronic lymphocytic leukemia.
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
CROWN (NCT03052608) is a phase 3 clinical trial evaluating progression free survival with the use of loratinib in patients with advanced ALK+ NSCLC.
Management of Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoietin Stimulating Agent (ESA) Treatment
The aim of this study is to describe the demographic, clinical, and treatment characteristics of patients with LRMDS who were managed by physicians at Florida…
Myeloma Molecular Profiling Reveals Unique Copy Number and Expression Subtypes
Findings from a molecular analysis of the CoMMpass study identified copy number and expression subtypes of high-risk, newly diagnosed multiple myeloma.
DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets
T-DXd showcased overall and intracranial activity in patients with HER2-positive metastatic breast cancer with stable and active brain metastases.
Tivozanib Monotherapy Bests Lower-Dose Tivozanib Plus Nivolumab in Metastatic RCC
The addition of nivolumab to tivozanib did not improve outcomes in metastatic RCC and 1.34 mg of tivozanib monotherapy may be considered as a second-line…
Belzutifan Maintains PFS, ORR Benefits in Previously Treated Advanced Clear Cell RCC
Belzutifan improved PFS and ORR but failed to deliver a significant improvement in OS vs everolimus in pretreated advanced clear cell renal cell carcinoma.